• Praeruptorin A: Translational Impact from Mechanism to Metas

  2026-05-01

  This thought-leadership article explores Praeruptorin A—a plant-derived angular pyranocoumarin compound—in the context of its mechanistic effects on metastasis, inflammation, and ferroptosis. Integrating recent evidence and best practices, it guides translational researchers on maximizing Praeruptorin A’s experimental and preclinical potential, with a focus on hepatocellular carcinoma, ulcerative colitis, and cardioprotection.

• Bleomycin Sulfate: Practical Guidance for DNA Damage & Fibro

  2026-05-01

  Bleomycin Sulfate (Blenoxane) is a glycopeptide antibiotic used by researchers as a DNA strand-break inducer and fibrosis model agent. It reliably models chemotherapy-induced DNA damage and pulmonary fibrosis, but should not be used in protocols requiring ethanol solubility or extended solution storage. This article offers actionable setup, parameter, and troubleshooting guidance for robust in vitro and in vivo workflows.

• Applied Workflows with 5-Aminolevulinic acid HCl in Heme Res

  2026-04-30

  Discover how 5-Aminolevulinic acid HCl empowers advanced heme biosynthesis studies and immune evasion models, including Salmonella-macrophage interactions and tumor imaging. Protocol enhancements and troubleshooting tips maximize reproducibility for both pathogen and cancer research.

• SB 431542: ALK5 Inhibitor for TGF-β Pathway Research Excelle

  2026-04-30

  SB 431542, a highly selective ALK5 inhibitor from APExBIO, empowers researchers to dissect TGF-β-dependent mechanisms with precision. Its proven performance in Smad2 pathway inhibition, anti-tumor immunity, and advanced fibrosis models sets a new standard for reproducible, data-driven workflows.

• DMH-1 (ALK2 Inhibitor): Unlocking Controlled Differentiation

  2026-04-29

  Explore how DMH1, a selective ALK2 inhibitor, empowers organoid and non-small cell lung cancer research by enabling precise modulation of cell fate and proliferation. This article uniquely bridges mechanistic insights with practical assay optimization for translational scientists.

• THZ1: Covalent CDK7 Inhibitor Benchmarks in T-ALL Research

  2026-04-29

  THZ1 is a potent, selective covalent CDK7 inhibitor with irreversible action and nanomolar efficacy in T-ALL models. Its unique mechanism involves covalent modification outside the kinase domain, driving robust transcription regulation inhibition. This article details evidence, workflows, and limitations for THZ1 in cancer biology.

• Lignans from Rosemary Roots: Novel Anti-Inflammatory Agents

  2026-04-28

  This study systematically isolated and characterized eight lignans and four phenylpropanoids from the roots of Rosmarinus officinalis, including three previously unknown compounds. Several of these lignans demonstrated potent, dose-dependent inhibition of nitric oxide production in LPS-stimulated macrophages, highlighting rosemary roots as a promising source of anti-inflammatory agents.

• 4-Phenylbutyric Acid: Optimizing ER Stress Assays in Cell Mo

  2026-04-28

  4-Phenylbutyric acid (4-PBA) from APExBIO sets the benchmark for reproducible endoplasmic reticulum (ER) stress modulation, enabling precise apoptosis and autophagy research. This article delivers actionable protocol enhancements, advanced troubleshooting, and real-world insights—bridging foundational studies and next-generation disease models.

• Baicalin and KEAP1-NRF2/HO-1 Pathway Modulation in Research

  2026-04-27

  Baicalin, a high-purity flavone glycoside from Scutellaria baicalensis, empowers researchers to precisely modulate KEAP1-NRF2/HO-1 and TGF-β1/p-Smad3 signaling in cutting-edge cancer and neuroplasticity studies. Its validated application in both ocular dominance plasticity and cancer sensitization sets a new standard for translational workflows.

• Cyclosporin: Mechanistic Precision in Translational Immunolo

  2026-04-27

  This article delivers a mechanistic and strategic synthesis for translational researchers using Cyclosporin A. It dissects the role of cyclophilin A in immunosuppression, contextualizes experimental design with evidence-backed protocol guidance, and positions APExBIO’s Cyclosporin as a research-grade benchmark. Bridging foundational biology with translational impact, it provides a nuanced, evidence-labeled roadmap for immunology and mitochondrial research.

• CHIR-99021 (CT99021): Optimizing Stem Cell Differentiation W

  2026-04-26

  CHIR-99021 (CT99021) is a benchmark GSK-3 inhibitor, enabling precise Wnt/β-catenin pathway control for robust stem cell applications. Leveraging new 3D neurovascular co-culture insights and best practices, researchers can now streamline differentiation protocols and troubleshoot common pitfalls with enhanced reproducibility.

• Mitochondrial IRF3 Links Mitophagy Disruption to Pulmonary F

  2026-04-25

  This study uncovers a novel mechanism in which mitochondrial IRF3 impairs mitophagy and induces ferroptosis in alveolar epithelial cells, driving pulmonary fibrosis progression. These findings highlight a new therapeutic target at the intersection of inflammation, mitochondrial quality control, and regulated cell death.

• PXR Activation Shields Against Cholestatic Liver Injury via

  2026-04-24

  This study demonstrates that activation of the pregnane X receptor (PXR) with pregnenolone-16α-carbonitrile protects against cholestatic liver injury in mice by suppressing both canonical and non-canonical hepatocyte pyroptosis. The findings uncover distinct anti-inflammatory pathways, positioning PXR as a high-value therapeutic target for cholestatic diseases.

• Bleomycin Sulfate Workflows: Pulmonary Fibrosis & DNA Damage

  2026-04-24

  Bleomycin Sulfate (Blenoxane) is the gold-standard tool for modeling DNA strand breaks and pulmonary fibrosis, enabling precise pathway interrogation in oncology and fibrotic research. This guide translates cutting-edge findings and vendor-supplied expertise into actionable protocols, troubleshooting strategies, and advanced use-cases for reproducible results.

• A 83-01: ALK-5 Inhibitor Transforming Organoid and EMT Resea

  2026-04-23

  A 83-01, a selective ALK-5 inhibitor from APExBIO, redefines experimental control in TGF-β signaling, organoid differentiation, and EMT modeling. Its nanomolar potency and robust Smad-dependent transcription suppression unlock reproducible, tunable protocols for high-diversity organoid systems and advanced disease modeling.

16100 records 1/1074 page Next 12345 下5页 Last page